SCHEMBL5364065

SCHEMBL5364065

COCCOc1cc2nccc(Oc3ccc(N)c(Cl)c3)c2cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.50
KDR P35968 17/20 0.47
AURKB Q96GD4 6/20 0.47
AURKA O14965 6/20 0.47
TEK Q02763 6/20 0.47
MET P08581 5/20 0.47
PDGFRA P16234 5/20 0.47
FLT1 P17948 3/20 0.47
PDGFRB P09619 3/20 0.47
ABL1 P00519 2/20 0.47
RET P07949 2/20 0.47
KIT P10721 2/20 0.47
FGFR1 P11362 2/20 0.47
FLT4 P35916 2/20 0.47
RIPK2 O43353 1/20 0.47
ERN1 O75460 1/20 0.47
STK10 O94804 1/20 0.47
MAP3K6 O95382 1/20 0.47
ESR1 P03372 1/20 0.47
ADORA3 P0DMS8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14540583 0.92 KDR (0.54) AXLKDRAURKBAURKATEK
SCHEMBL22505715 0.92 AXL (0.59) AXLKDRAURKBAURKATEK
SCHEMBL1892397 0.91 AXL (0.51) AXLKDRAURKBAURKATEK
SCHEMBL22505666 0.90 KDR (0.52) AXLKDRAURKBAURKATEK
SCHEMBL14540932 0.90 AXL (0.51) AXLKDRAURKBAURKATEK
SCHEMBL3504196 0.90 KDR (0.56) AXLKDRAURKBAURKATEK
Methylamine SCHEMBL22505580 0.89 KDR (0.55) AXLKDRAURKBAURKATEK
SCHEMBL14540914 0.89 KDR (0.58) AXLKDRAURKBAURKATEK
SCHEMBL14540588 0.88 PDGFRA (0.48) AXLKDRAURKBAURKATEK
SCHEMBL14540940 0.86 KDR (0.52) AXLKDRAURKBAURKATEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
EP-1415987-B1 NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS EISAI R&D MAN CO LTD (JP) 2007-02-28 EP disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R AXL 515/4885KDR 22/4885AURKB 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.